PROMOMED expands the geography of its presence: The company has opened an international division in China
13.11.2026
13.11.2026
PROMOMED became the winner of the IP Russia Awards 2026, winning in five nominations at once. The jury noted the company's work in the field of intellectual property protection and management, trademark protection and dispute resolution on exclusive rights. Among the submitted projects, a court case on a compulsory license for the veterinary drug Rabectra® is highlighted [*].
IP Russia Awards is the first Russian intellectual property award, which is supported by Rospatent and FIPS. It celebrates the achievements of specialists and organizations and helps spread professional practices in this field. The award ceremony took place on November 13, 2026, as part of the 27th Intellectual Property Forum. In total, the award provided 12 nominations for business, in five of which the winner was PROMOMED. The awards reflected the different areas of work of the Intellectual Property Directorate, from building a system for protecting developments to protecting the company's rights in court and managing its brands.
The victory in the IP Disputes nomination was brought by the case of the compulsory license for Rabectra®. PROMOMED sought the right to use these patents for the release of a Russian drug against the background of limited availability in Russia of the original product with the same active ingredient. In June 2026, PROMOMED received the right to use patents based on decisions of the courts of first instance and appeal. In September, the Intellectual Property Rights Court overturned the decisions and sent the case for a new hearing, but on September 30, the Supreme Court of the Russian Federation overturned the ruling of the Intellectual Property Rights Court and upheld the original decisions. The change of court decisions and the issue of the legality of the drug's release during the license period attracted the attention of the professional community and the media to the dispute. At the forum, Maria Porokhnya, Director of Intellectual Property at PROMMED, presented the report "Rabectra® against Bravecto®: the first compulsory license after the Constitutional Court Ruling 13-P", in which she reviewed the judicial case and its significance for law enforcement practice.
Four more awards were given to the work of the company's patent and trademark departments over the past year. PROMOMED won in the nominations "The best REED protection and management Strategy in the pharmaceutical industry and medicine", "The best practice of protecting means of individualization", "The best commercialization of exclusive rights to means of individualization" and "The most creative trademark registration".
Along with participating in the competition, PROMOMED became a partner in a special nomination dedicated to the practices of intellectual property management in universities. The company consistently supports student initiatives and domestic higher education. The partnership in the award was a continuation of this work and an opportunity to pay attention to the training of specialists who will develop the field of intellectual property.
"It is the mission of our team to set the bar and support the development of intellectual property in universities, to conduct educational and educational activities in parallel with internal work for the benefit of business. The development of technological sovereignty is impossible without a strong sphere of protection and protection of intellectual property in all areas of the economy," said Maria Porokhnya.
_________________________________________________
* - There are contraindications. It is necessary to read the Instructions for use of the drug.
Stay informed
Stay informed
Get the most interesting news and publications first!
Sent successfully!
Press office
To request a press release or interview, please contact our press office